| Featured Story | By Nick Paul Taylor The wait for an oral antiviral against COVID-19 may almost be over. Friday, Merck reported its prospect halved the risk of hospitalization and death in phase 3, spurring it to stop the study and race to get emergency use authorization. read more |
| |
|---|
|
Top Stories By Kyle LaHucik What will BioNTech do after helping Pfizer make a COVID-19 vaccine that has been delivered to hundreds of millions of people worldwide? Biotech insiders and the general public alike now have an answer: A phase 2 study of a different mRNA in a vaccine for colorectal cancer. read more By Kyle LaHucik Novartis-backed Cellular Biomedicine Group is hitting the ground running as a newly private company with $120 million from AstraZeneca and others after delisting from the Nasdaq in February. read more Sponsored by: Premier Research With the shift from traditional chemotherapy agents to innovative immuno-oncology drugs and cell and gene therapies, oncology clinical trials have increased in complexity. read more By Annalee Armstrong Another small biotech trying to make a play in COVID-19 treatment has hit a brick wall in clinic trials. This time it’s Laurent Pharmaceuticals, which reported that an oral candidate for hospitalized patients was unsuccessful in a midstage trial. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Kyle LaHucik Ventyx Biosciences is headed from California to Wall Street with plans for a customary $100 million IPO just six months after consolidating two biotechs under its roof. read more By Nick Paul Taylor Investors have bought into Micreos’ vision for a sustainable alternative to antibiotics. With backers putting up 32 million euros ($37 million), Micreos is now poised to show whether its platform can generate more targeted, harder-to-resist ways of taking out bacteria. read more By Kyle LaHucik A UCSD-led team reported a potential way to prevent a newly discovered genetic condition called Zaki syndrome, which impacts the prenatal development of the eyes, brain, hands, kidneys and heart. The researchers found that children born with Zaki had genetic mutations that, in preclinical models, could be successfully targeted with a drug. read more By Andrea Park Hemanext is hoping to give standard blood storage practices a transfusion of their own—but of innovation, rather than blood cells. read more By Anastassia Gliadkovskaya A network of right-wing health providers has profited at least $15 million off of tens of thousands of patients seeking consultations for and buying ineffective COVID-19 treatments including hydroxychloroquine and ivermectin, The Intercept reported Tuesday. read more By Angus Liu Merck hopes its $11.5 billion Acceleron buy will quickly wrap up in the fourth quarter. But revolt from an activist investor threatens to derail that plan. Avoro Capital, known for nixing Immunomedics’ tie-up with Seattle Genetics, slammed Merck’s $180-apiece price “drastically undervalues” Acceleron. read more By Arlene Weintraub University of California researchers produced a map of protein interactions in cancer, uncovering previously unrecognized mutations they believe could drive metastasis. The detailed insights that emerged could explain disparities in the effectiveness of cancer drugs while also leading to new drug targets, they believe. read more By Angus Liu Biogen and Eisai have started an FDA rolling submission for another Alzheimer's disease drug. Samsung Biologics' long-term partnership with Roche has grown in value. Otsuka has penned a near-$1 billion deal for four Sunovion neuropsychiatric candidates. And more. read more By Kyle LaHucik FDA's vaccines office is now headed by Peter Marks after the agency's top two vaccine officials questioned the need for booster doses last month as they head toward the exit later this fall. Houston biotech incubator Sporos Biosciences snagged ex-Ovid Therapeutics Chief Medical Officer Amit Rakhit as its new CEO. In spinning off its gene therapy unit, Amicus' CEO will head to the new company being launched via a SPAC. read more Resources Sponsored By: Bioclinica Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF. Sponsored By: Bioclinica This whitepaper addresses where AI can make the biggest impact in clinical trials. Sponsored by: WCG Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
